<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04510337</url>
  </required_header>
  <id_info>
    <org_study_id>201617031.2P</org_study_id>
    <nct_id>NCT04510337</nct_id>
  </id_info>
  <brief_title>Does Adding Magnesium Sulphate to Low Dose Rocuronium Affects Depth of Blockade</brief_title>
  <official_title>Does Adding Magnesium Sulphate to Low Dose Rocuronium Affects the Depth of Blockade in Cancer Patients Undergoing Direct Laryngoscope Surgical Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Egypt</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aim is to compare the effect of magnesium sulphate combined with low dose&#xD;
      rocuronium versus standard dose rocuronium&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparing the effect of magnesium sulphate combined to low dose rocuronium versus standard&#xD;
      dose rocuronium in cancer patients undergoing direct laryngoscopy for laryngeal tumors&#xD;
      regarding intubating conditions, intraoperative relaxation, depth of anesthesia and recovery&#xD;
      time.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2, 2018</start_date>
  <completion_date type="Actual">February 20, 2021</completion_date>
  <primary_completion_date type="Actual">February 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Onset and duration of muscle relaxant</measure>
    <time_frame>90 minutes</time_frame>
    <description>Onset time of muscle relaxant and duration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree of muscle relaxation</measure>
    <time_frame>90 minutes</time_frame>
    <description>depth of blockade</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Standard rocuronium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients received rocuronium 0.6mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnesium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients received 100 ml saline with 50mg/kg magnesium sulphate infusion over 10 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard rocuronium dose</intervention_name>
    <description>0.6 mg/kg rocuronium during induction of anesthesia</description>
    <arm_group_label>Standard rocuronium</arm_group_label>
    <other_name>standard dose rocuronium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulfate</intervention_name>
    <description>50 mg/kg magnesium sulphate added to 0.40 mg/kg rocuronium</description>
    <arm_group_label>Magnesium</arm_group_label>
    <other_name>low dose rocuronium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with Laryngeal tumors&#xD;
&#xD;
        ASA I-II&#xD;
&#xD;
        Age 30-70 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Renal and or hepatic insufficiency&#xD;
&#xD;
        Neuromuscular disease&#xD;
&#xD;
        Large glottic and/or supra-glottic lesions with or without breathing difficulties&#xD;
&#xD;
        Known allergy to any of the used drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walaa Y Elsabeeny, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lecturer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed A Wadod, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lecturer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Cairo</city>
        <zip>11796</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 10, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute, Egypt</investigator_affiliation>
    <investigator_full_name>Walaa Youssef Elsabeeny</investigator_full_name>
    <investigator_title>Lecturer of anesthesia and pain management</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

